AstraZeneca ((AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is currently conducting a study titled ‘A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)’. The study aims to assess the safety, tolerability, and efficacy of AZD5492, a novel T cell-engaging antibody, in treating relapsed or refractory B-cell malignancies.
The intervention under investigation is AZD5492, a CD8/TCR based T-cell engaging antibody targeting CD20, administered subcutaneously. Its purpose is to offer a new treatment option for patients with challenging B-cell malignancies.
This interventional study follows a sequential model with no masking, focusing on treatment as its primary purpose. It includes individual modules to evaluate various aspects of AZD5492, both as a monotherapy and in combination with other anticancer treatments.
The study began on September 18, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 4, 2025, indicating ongoing recruitment and progress.
The outcome of this study could significantly influence AstraZeneca’s stock performance and investor sentiment, especially if AZD5492 proves to be a successful treatment. This development could also impact the competitive landscape in the oncology sector, where innovative therapies are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.